相关实验视频

Updated: Jul 11, 2025

Functional Near-Infrared Spectroscopy Hyperscanning Study in Psychological Counseling

Functional Near-Infrared Spectroscopy Hyperscanning Study in Psychological Counseling

Published on: January 17, 2025

临床试验:对于耐火性易怒肠综合征的肠导向催眠疗法的反应的预测因素,一项后期分析

Jade Devenney^1,2, Syed S Hasan^1,2, Julie Morris²

¹Neurogastroenterology Unit, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

Alimentary pharmacology & therapeutics

|November 6, 2023

概括

肠道导向的催眠疗法有效地治疗了易怒肠综合征 (IBS). 在基线有更多胃肠道和非胃肠道症状的患者更有可能从这种IBS治疗中受益.

科学领域:

胃肠病学胃肠病学
精神病体医学是一种精神病体医学.
行为治疗是一种行为疗法.

背景情况:

肠道导向的催眠疗法是对刺激性肠综合征 (IBS) 的有效治疗方法.
尽管有效,但肠道导向催眠疗法的可用性有限,需要患者选择以获得最佳结果.
确定最有可能反应的患者对于资源分配至关重要.

研究的目的:

研究基线患者特征,预测IBS患者对肠道导向催眠疗法的治疗反应.
为了确定成功减少耐火性IBS症状的预测因素.

主要方法:

从随机试验中对448名耐火罗马IIIIBS患者的二次分析.
在响应者和非响应者之间比较基线特征 (年龄,性别,IBS亚型,生活质量,IBS-SSS,非结肠症状,HAD分数).
响应被定义为IBS-SSS减少≥50点或疼痛严重程度减少≥30%.

主要成果:

76.3%的患者在IBS-SSS下降了≥50点.
受访者表现出更高的基线非结肠症状得分.
改善的疼痛评分与更高的基线IBS-SSS和更低的HAD-抑郁症评分相关.
患有高HAD焦虑分数的患者中,放学率更高.

结论:

患有更重的胃肠道和肠外症状的患者更有可能从肠道导向的催眠疗法中受益于耐火性IBS.
评估胃肠道,体质和心理症状概况,可以帮助选择适合这种干预的候选人.
这种方法可以优化有限的肠道导向催眠疗法资源的使用.

更多相关视频

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

Method for Simultaneous fMRI/EEG Data Collection during a Focused Attention Suggestion for Differential Thermal Sensation

Method for Simultaneous fMRI/EEG Data Collection during a Focused Attention Suggestion for Differential Thermal Sensation

Published on: January 5, 2014

相关概念视频

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Irritable Bowel Syndrome III: Medical and Nursing Management

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Assessment of the Gastrointestinal System I: Subjective Data

Assessment of the Gastrointestinal System I: Subjective Data

Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...